OTC : SNPHF

Santen Pharmaceutical Co., Ltd.

$13.05 USD

$0 (0.0%)

Volume
2K
Average Volume
16
Market Capitalization
$4.2B
P/E Ratio
17.91
Dividend Yield
1.86%
Price Target
Year High
$13.06
Year Low
$8.88
Day High
—
Day Low
—
Payout Ratio
$0.34
Current Ratio
$2.60
Company Overview

OTC

Takeshi Ito

Drug Manufacturers - General

Healthcare

SNPHF

3968

JP

USD

https://www.santen.com

81 6 7664 8621

N/A

N/A

Liquidity Metrics

0.12

2.60

1.87

0.92

0.34

Sales & Valuation

$293.46B

2.25

2.24

17.92

112.78

Profitability

$115.04

$37.6B

12.81%

16.27%

13.15%

8.83%

P/E Metrics

17.91

1.85

1.85

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Poll Results

About Santen Pharmaceutical Co., Ltd. (OTC:SNPHF) Stock

Santen Pharmaceutical Co., Ltd. is a global enterprise specializing in the research, development, manufacturing, and commercialization of pharmaceuticals and medical devices. Headquartered in Osaka, Japan, its core focus lies in ophthalmology. The company boasts a robust pipeline of treatments for various eye conditions. For glaucoma and ocular hypertension, its offerings include DE-111 and DE-130A, both in Phase III clinical trials; DE-117, available in Japan; DE-126, currently in Phase IIb development; and DE-128, which is marketed in Europe and undergoing Phase II/III trials in the United States. Santen also addresses other ophthalmic conditions: DE-114A for allergic conjunctivitis, DE-076C for vernal keratoconjunctivitis, and DE-109, which is in Phase III development for uveitis. Its p ... ipeline further includes treatments for myopia, such as DE-127 (in Phase II/III in Japan and Phase III across Asia) and STN1013400 (in Phase I). Additionally, DE-089C has successfully completed Phase III clinical trials for dry eye treatment. Beyond prescription medications, Santen also provides over-the-counter (OTC) pharmaceutical products. Founded in Osaka, Japan, in 1890, the company adopted its current name, Santen Pharmaceutical Co., Ltd., in 1958, having previously operated as Santendo Pharmaceutical Co., Ltd.

Frequently Asked Questions

What is the current Santen Pharmaceutical Co., Ltd. (SNPHF) stock price?

Santen Pharmaceutical Co., Ltd.(OTC:SNPHF) stock price is $13.05 in the last trading session. During the trading session, SNPHF stock reached the peak price of $13.06 while $8.88 was the lowest point it dropped to. The percentage change in SNPHF stock occurred in the recent session was 0.0% while the dollar amount for the price change in SNPHF stock was $0.

SNPHF's industry and sector of operation?

The OTC listed SNPHF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of SNPHF?

Shinichi Teramachi | Corporation Officer, Head of Sales and Head of Japan Sales & Marketing
Takahiro Morita | Global Head of Core Principle & Sustainability and Corporate Officer
Takeshi Ito | President, Chief Executive Officer & Representative Director
Kaori Itagaki | General Manager of Investor Relations Group
Mika Masunari | Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer

How many employees does SNPHF have?

Number of SNPHF employees currently stands at 3968. SNPHF operates from Grand Front Osaka Tower A, Osaka, OS 530-8552, JP.

Link for SNPHF official website?

Official Website of SNPHF is: https://www.santen.com

How do I contact SNPHF?

SNPHF could be contacted at phone #81 6 7664 8621 and can also be accessed through its website. SNPHF operates from Grand Front Osaka Tower A, Osaka, OS 530-8552, JP.

How many shares of SNPHF are traded daily?

The average number of SNPHF shares traded daily for last 3 months was 16.

What is the market cap of SNPHF currently?

The market value of SNPHF currently stands at $4.2B with its latest stock price at $13.05